AmbiOnp: Solid Lipid Nanoparticles of Amphotericin B for Oral Administration

Journal of Biomedical Nanotechnology ◽

10.1166/jbn.2011.1332 ◽

2011 ◽

Vol 7 (5) ◽

pp. 632-639 ◽

Author(s):

Pratikkumar A. Patel ◽

Vandana B. Patravale

Keyword(s):

Oral Administration ◽

Amphotericin B ◽

Solid Lipid Nanoparticles ◽

Lipid Nanoparticles ◽

Download Full-text

Coalition of Biological Agent (Melatonin) With Chemotherapeutic Agent (Amphotericin B) for Combating Visceral Leishmaniasis via Oral Administration of Modified Solid Lipid Nanoparticles

ACS Biomaterials Science & Engineering ◽

10.1021/acsbiomaterials.1c00859 ◽

2021 ◽

Author(s):

Shabi Parvez ◽

Ganesh Yadagiri ◽

Kanika Arora ◽

Aaqib Javaid ◽

Anurag Kumar Kushwaha ◽

...

Keyword(s):

Visceral Leishmaniasis ◽

Oral Administration ◽

Amphotericin B ◽

Solid Lipid Nanoparticles ◽

Chemotherapeutic Agent ◽

Lipid Nanoparticles ◽

Biological Agent ◽

Download Full-text

Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B12-stearic acid conjugate

Materials Science and Engineering C ◽

10.1016/j.msec.2020.111279 ◽

2020 ◽

Vol 117 ◽

pp. 111279 ◽

Author(s):

Aakriti Singh ◽

Ganesh Yadagiri ◽

Shabi Parvez ◽

Om Prakash Singh ◽

Anurag Verma ◽

...

Keyword(s):

Stearic Acid ◽

Vitamin B12 ◽

Amphotericin B ◽

Solid Lipid Nanoparticles ◽

Lipid Nanoparticles ◽

Solid Lipid ◽

Download Full-text

Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration

International Journal of Pharmaceutics ◽

10.1016/j.ijpharm.2011.02.064 ◽

2011 ◽

Vol 410 (1-2) ◽

pp. 138-144 ◽

Author(s):

Cheng-Feng Luo ◽

Mu Yuan ◽

Min-Sheng Chen ◽

Shi-Ming Liu ◽

Liu Zhu ◽

...

Keyword(s):

Oral Administration ◽

Tissue Distribution ◽

Solid Lipid Nanoparticles ◽

Relative Bioavailability ◽

Lipid Nanoparticles ◽

Download Full-text

Design, Development, Characterization of Solid Lipid Nanoparticles for Oral Administration

Research Journal of Science and Technology ◽

10.5958/2349-2988.2020.00011.x ◽

2020 ◽

Vol 12 (1) ◽

pp. 79

Author(s):

S. D. Mankar ◽

Anjali Dama ◽

M.S. Bhosale ◽

S. S. Sidhheshwar

Keyword(s):

Oral Administration ◽

Solid Lipid Nanoparticles ◽

Lipid Nanoparticles ◽

Design Development ◽

Download Full-text

Pharmacokinetics, tissue distribution and relative bioavailability of geniposide-solid lipid nanoparticles following oral administration

Journal of Microencapsulation ◽

10.3109/02652048.2013.863396 ◽

2014 ◽

Vol 31 (4) ◽

pp. 382-389 ◽

Author(s):

Fugang Wang ◽

Juan Cao ◽

Jifu Hao ◽

Ke Liu

Keyword(s):

Oral Administration ◽

Tissue Distribution ◽

Solid Lipid Nanoparticles ◽

Relative Bioavailability ◽

Lipid Nanoparticles ◽

Download Full-text

Lipid Effects on Expulsion Rate of Amphotericin B from Solid Lipid Nanoparticles

AAPS PharmSciTech ◽

10.1208/s12249-013-0056-9 ◽

2013 ◽

Vol 15 (2) ◽

pp. 287-295 ◽

Author(s):

See Wei Tan ◽

Nashiru Billa

Keyword(s):

Amphotericin B ◽

Solid Lipid Nanoparticles ◽

Lipid Nanoparticles ◽

Expulsion Rate ◽

Download Full-text

Preparation, Pharmacokinetics and Body Distribution of Silymarin-Loaded Solid Lipid Nanoparticles After Oral Administration

Journal of Biomedical Nanotechnology ◽

10.1166/jbn.2007.024 ◽

2007 ◽

Vol 3 (2) ◽

pp. 195-202 ◽

Author(s):

Jun He ◽

Shixiang Hou ◽

Weigen Lu ◽

Lin Zhu ◽

Jianfang Feng

Keyword(s):

Oral Administration ◽

Solid Lipid Nanoparticles ◽

Lipid Nanoparticles ◽

Solid Lipid ◽

Body Distribution

Download Full-text

Amphotericin B loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): physicochemical and solid-solution state characterizations

Drug Development and Industrial Pharmacy ◽

10.1080/03639045.2019.1569023 ◽

2019 ◽

Vol 45 (4) ◽

pp. 560-567 ◽

Author(s):

Phatsawee Jansook ◽

Zoltán Fülöp ◽

Garnpimol C. Ritthidej

Keyword(s):

Solid Solution ◽

Amphotericin B ◽

Solid Lipid Nanoparticles ◽

Lipid Nanoparticles ◽

Nanostructured Lipid Carrier ◽

Solution State ◽

Download Full-text

Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis

Scientific Reports ◽

10.1038/s41598-020-69276-5 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Shabi Parvez ◽

Ganesh Yadagiri ◽

Mallikarjuna Rao Gedda ◽

Aakriti Singh ◽

Om Prakash Singh ◽

...

Keyword(s):

Visceral Leishmaniasis ◽

Amphotericin B ◽

Solid Lipid Nanoparticles ◽

Lipid Nanoparticles ◽

Download Full-text

Encapsulating Rifampicin into SLNs: A Viable Option for Managing its Bioavailability Issues Upon Co-Delivery with Isoniazid

Current Drug Delivery ◽

10.2174/1567201817666200220121306 ◽

2020 ◽

Vol 17 (4) ◽

pp. 343-347

Author(s):

Harinder Singh ◽

Ruchi Sood ◽

Tridib Chaira ◽

Alka Khanna ◽

Dilip J Upadhaya ◽

...

Keyword(s):

Plasma Concentration ◽

Oral Administration ◽

Solid Lipid Nanoparticles ◽

Lipid Nanoparticles ◽

Acidic Ph ◽

Viable Option ◽

Time Points ◽

Background: Rifampicin is known to degrade at the acidic pH of the stomach, especially in the presence of isoniazid. Although isoniazid also degrades partially, its degradation is reversible. Objective: Presently, we provide a proof of the fact that the simultaneous oral administration of rifampicin (RIF), upon incorporation into solid lipid nanoparticles (RIF-SLNs), with isoniazid (INH) overcomes its INH-induced degradation and improves its oral bioavailability in rats. Methods: Solid lipid nanoparticles of RIF (RIF-SLNs) were prepared using a novel and patented method. The effect of INH was investigated on in vivo bioavailability of RIF both in its free and encapsulated (RIF-SLNs) form, after oral administration to rats. Results: Cmax and AUC0-∞ of RIF increased 158 % and 125 %, respectively, upon incorporation into SLNs versus free RIF when combined with INH. The Tmax decreased from 5.67 h to 3.3 h, and the plasma concentration of RIF remained above its MIC (8 μg/ml) at all the tested time points starting with 15 min, when administered as RIF-SLNs in combination with INH. Conclusions: The results confirm the scope of combining RIF-SLNs with INH to overcome the bioavailability of free RIF when combined with INH, especially in fixed dose combinations.

Download Full-text